GDARISK, Poland (PRWEB)
May 27, 2023

The price has been awarded to Evidence Prime for its flagship product, Laser AI. This advanced solution, based on natural language processing (NLP) and artificial intelligence (AI), helps life sciences organizations around the world make data-driven decisions, streamline processes, and enhance operational efficiency. Laser AI has significantly improved the way organizations manage and analyze vast amounts of data, supporting the creation of so-called Living Systematic Reviews (LSR) – systematic reviews updated on an ongoing basis.

“We are thrilled to receive the main prize for Best Technological Solution in the Eagle of Innovation competition,” said Pawel Kunstman, President of Evidence Prime. “In 2018, we committed all our efforts to the development of Natural Language Processing technologies capable of handling the overwhelming volume of evidence that needs to be analyzed to make the right healthcare decisions. This award is a testament to the hard work and dedication of our talented team, which made achieving this goal possible. We are grateful for this honour and remain committed to delivering cutting-edge solutions that drive transformative change in the life sciences industry.”

Evidence Prime received the main prize in the category of the Best Technological Solution during the Eagle of Innovation award ceremony on the 24th of May, 2023, in Gdańsk, Poland. The event gathered influential leaders, industry experts, and key stakeholders to celebrate the achievements of innovative companies and their contributions to the European technological landscape.

About Evidence Prime:

Evidence Prime is a global leader in the market of evidence-based healthcare guidelines and systematic review authoring, focusing on innovative, AI-driven tools for this market. Its flagship product, Laser AI, is a revolutionary system for automating the development of systematic reviews in healthcare. Already in use by leading US and German governmental institutions as well as major corporations, Laser AI streamlines the review process, allowing for more efficient and accurate analysis of healthcare data. With its commitment to data security, Evidence Prime stands out as the most secure Software-as-a-Service (SaaS) provider in its domain, bringing the safest and most effective solutions to accelerate research efforts. For more information about Evidence Prime, its groundbreaking products, and its commitment to security, visit https://laser.ai and https://evidenceprime.com.

Share article on social media or email:

BATON ROUGE, La. (PRWEB)
May 27, 2023

Right at Home, the 700-plus location in-home care concept helping seniors and adults with disabilities live comfortably at home, is looking to expand in Baton Rouge, Louisiana. The opportunity gives local entrepreneurs a chance to make a difference in their communities and provide peace of mind to families needing care.

Right at Home employs professionally trained caregivers to provide care and assistance to seniors and adults with disabilities who wish to remain in the comfort and safety of their own home or current living arrangement. With over 28 years of experience providing essential care in more than 700 locations across seven countries, Right at Home has become one of the world’s largest in-home care franchises.

With persons aged 65 and over making up 14.2% of the population, Baton Rouge is primed for Right at Home’s services. Additionally, the capital city has been growing as a hotspot for new businesses in recent years. In fact, the percent of new companies in Baton Rouge experienced quarter-over-quarter growth 13 of the last 15 quarters, while more than 3,300 new establishments exist in the region compared to Q1 2018.

“Right at Home starts with our passionate franchise owners, and we’re excited to partner with the people of Baton Rouge,” said Jennifer Chaney, Vice President of Franchise Development. “We are seeking passionate individuals who aren’t just looking for a business to make a living. Entrepreneurs should choose Right at Home to make a positive impact on their communities and the people for whom they provide care. Our mission is to improve the quality of life for everyone that we serve.”

Currently, Right at Home doesn’t have a presence in the market, but already has three territories within the state of Louisiana. With its eyes on Baton Rouge, the industry-leading in-home care concept is seeking franchise partners to provide its much-needed services within two territories in the market.

Right at Home is seeing an increased demand for quality in-home care services across the country as the baby boomer generation reaches its senior years. During 2020 and 2021, the franchise not only survived the height of the pandemic but came out of it stronger than ever– exceeding growth goals by 40%. And in 2022, Right at Home picked up even more momentum as it continued to bring its best-in-class in-home care services to families in new markets across the country. This year, Right at Home is looking forward to building on that growth, including in Baton Rouge.

ABOUT RIGHT AT HOME:

Founded in 1995, Right at Home offers in-home care to seniors and adults with disabilities who want to live independently. Most Right at Home offices are independently owned and operated and directly employ and supervise all caregiving staff. Each caregiver is thoroughly screened, trained and bonded/insured before entering a client’s home. Right at Home’s global office is based in Omaha, Nebraska, with more than 700 franchise locations in the U.S. and six other countries. For more information on Right at Home, visit http://www.rightathome.net or read the Right at Home blog at http://www.rightathome.net/blog.

Share article on social media or email:

NASHVILLE (PRWEB)
May 26, 2023

The Beryl Institute releases “Listening Organizations: Elevating the Human Experience in Healthcare through the Lived Experience of Patients & Families,” identifying ways organizations are acting on the feedback of patient and family advisors (PFAs) and improving care experience. The paper includes the global contributions of pioneers, leaders and volunteer advisors in the field of patient and family engagement, acknowledging the current gaps in advisor utilization and recommending ways to elevate their voice in strategic healthcare improvement. The paper highlights success stories of listening organizations and takeaways for becoming one.

Key takeaways include:

• 
  PFAs are considered important, but their lived experience is not always fully appreciated by healthcare organizations.
• Listening organizations embed diverse patient and family advisors into committees, education and research, and in strategic planning.
• Elevating the role of PFAs requires partnerships with leadership, providers and the staff.

“Over the last two years, more healthcare organizations are engaging the voices of patient and family advisors,” said Jason Wolf, President & CEO of The Beryl Institute. “Increased engagement is a good first step toward the evolution of PFA utilization, but it is the power of listening to the lived experience through this engagement and taking action on the feedback that will impact improvement efforts.”

To access the executive brief, PX paper, and patient reflection visit https://www.theberylinstitute.org/page/PXPapers

###

About The Beryl Institute

The Beryl Institute is a global community of healthcare professionals and experience champions committed to transforming the human experience in healthcare. As a pioneer and leader of the experience movement and patient experience profession for more than a decade, the Institute offers unparalleled access to unbiased research and proven practices, networking and professional development opportunities and a safe, neutral space to exchange ideas and learn from others.

We define the patient experience as the sum of all interactions, shaped by an organization’s culture, that influence patient perceptions across the continuum of care. We believe human experience is grounded in the experiences of patients and families, members of the heal

Share article on social media or email:

NEW YORK (PRWEB)
May 26, 2023

Patients with moderate-to-severe Crohn’s disease now have a new treatment option to suppress their intestinal inflammation and painful symptoms, and help them maintain their relief.

Data from a phase 3 trial published today in The New England Journal of Medicine show that upadacitinib—a breakthrough, once-daily oral medication—helps patients achieve and maintain clinical and endoscopic remission. As a result, upadacitinib garnered Food and Drug Administration approval on Thursday, May 18.

Crohn’s disease, a chronic inflammatory bowel disorder affecting millions worldwide, has long presented a significant challenge for both patients and health care providers. Existing treatment options often fall short in achieving sustained remission and controlling symptoms. However, the results of the upadacitinib study herald a promising breakthrough in managing this complex condition.

Corresponding author Jean-Frederic Colombel, MD, notes, “Upadacitinib addresses an unmet need in the treatment of Crohn’s disease and allows patients access to an oral medication that could put them in clinical and endoscopic remission. This therapy has the potential to transform the lives of individuals battling this chronic condition and offers a new hope for improved quality of life.” Dr. Colombel is the co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at The Mount Sinai Hospital in New York City and Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai.

Upadacitinib is a selective Janus kinase (JAK) inhibitor. It precisely targets the underlying pathways of inflammation, thereby mitigating the symptoms and potentially minimizing the risk of adverse events associated with immunosuppression.

The study spanned 43 countries and 277 sites, and enrolled a diverse group of patients 18 to 75 years old who had moderate-to-severe Crohn’s disease for at least three months.

Participants were randomly assigned to receive 45 mg of upadacitinib or placebo (2:1) for induction therapy to assess its effectiveness in achieving remission in two double-blind phase 3 trials, U-EXCEL and U-EXCEED. The medication was taken once daily for 12 weeks. Patients who had a clinical response to upadacitinib induction therapy were then randomly assigned in the U-ENDURE maintenance trial to receive 15 mg or 30 mg of upadacitinib, or placebo (1:1:1) once daily for 52 weeks. The maintenance phase evaluated the drug’s ability to sustain remission and prevent relapse. (U-EXCEED had an additional 12-week open-label, active single-group induction period to allow for the accrual of enough patients for entry into U-ENDURE.)

The primary endpoints for induction (week 12) and maintenance (week 52) were clinical remission (defined as a Crohn’s Disease Activity Index score of less than 150 on a range of 0 to 600, with higher scores indicating more severe disease activity) and endoscopic response (defined as a decrease in the Simple Endoscopic Score for Crohn’s Disease [SES-CD; range, 0 to 56, with higher scores indicating more severe disease] of greater than 50% from baseline of the induction trial [or for patients with an SES-CD of 4 at baseline, a decrease of greater than or equal to 2 points from baseline]).

Upadacitinib demonstrated superior efficacy over placebo, with a statistically significant proportion of patients achieving clinical remission after induction therapy. During the maintenance phase, the therapy substantially reduced the rate of disease relapse, illustrating its potential as a long-term treatment option for Crohn’s disease.

###

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

LONG ISLAND, N.Y. (PRWEB)
May 26, 2023

The DRIPBaR is thrilled to announce the opening of its newest location in Long Island, NY on June 5th. This marks the newest location for the franchise, with approximately 500+ additional locations in the pipeline.

The DRIPBaR Long Island will offer all of the standard DRIPBaR services, including IV vitamin therapy and IM Quick Shots. This particular location will also offer a suite of additional wellness services – including Mobile Services, an Infrared Sauna, and Halotherapy.

Owned and operated by Peter Anastasian, Charlie Massimo, Chris Campese, and Frank Califano, The DRIPBaR Long Island is the newest addition to the growing DRIPBaR franchise. Passionate about providing relief to their community, the owners aim to make IV therapy accessible to those seeking a natural and effective way to support their health and well-being. Their goal is to deliver top-quality IV therapy services and help individuals achieve their wellness goals.

At The DRIPBaR, clients can expect a variety of services tailored to help them achieve optimal wellness. Whether someone is in need of a quick boost or a long-term wellness solution, there’s an IV drip to fit their unique needs. Each drip is carefully formulated with a customized blend of vitamins, minerals, and nutrients to promote optimal health and vitality.

To celebrate their arrival, The DRIPBaR Long Island is offering 50% off any IV drip and a FREE B12 Quick Shot if you book before June 5th. Appointments can be booked here!

About The DRIPBaR

Founded in 2016, The DRIPBaR is a nationwide franchise focused on helping people obtain their best physical and mental health using intravenous therapies. Through advances in cellular and biological science, The DRIPBaR helps clients fight the consequences of chronic illness, address the effects of aging, and achieve balanced wellness. With a focus on ever-evolving treatments and medical advancements, the franchise hopes to shorten the gap between concierge and treatment-based medicine. The DRIPBaR already has more than 600 additional locations in various stages of development across 28 states, with nearly 40 currently open and operating. For more information, visit http://www.thedripbar.com.

The DRIPBR Long Island

6079 Jericho Turnpike

Commack, NY 11725

(516) 543-3988

LongIsland166Team@TheDRIPBaR.com

Share article on social media or email: